Photo by curvd from unsplash
Thalidomide and closely related analogues are used clinically for their immunomodulatory and antiangiogenic properties mediated by the inhibition of the proinflammatory cytokine tumor necrosis factor α. Neuroinflammation and angiogenesis contribute… Click to show full abstract
Thalidomide and closely related analogues are used clinically for their immunomodulatory and antiangiogenic properties mediated by the inhibition of the proinflammatory cytokine tumor necrosis factor α. Neuroinflammation and angiogenesis contribute to classical neuronal mechanisms underpinning the pathophysiology of l‐dopa‐induced dyskinesia, a motor complication associated with l‐dopa therapy in Parkinson's disease. The efficacy of thalidomide and the more potent derivative 3,6′‐dithiothalidomide on dyskinesia was tested in the 6‐hydroxydopamine Parkinson's disease model.
Journal Title: Movement Disorders
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!